Version history

{
  "session_id": "sess_SDA-BIOMNI-FINE_MAP-215bc2c6",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Novel Hypotheses: Bayesian Fine-Mapping of Top 25 AD GWAS Loci\n\n---\n\n## Hypothesis 1: Strong LD Structure Enables High-Posterior Credible Sets\n\n**Description:** Loci exhibiting strong linkage disequilibrium patterns—particularly the APOE-TOMM40 region on chromosome 19 and the ABI3 locus—will yield narrow credible sets (<10 variants) with high posterior probability (>0.90). The LD structure creates natural statistical \"bins\" that Bayesian methods can exploit, combined with the relatively large effect sizes at these loci.\n\n**Target Gene/Protein:** APOE (apolipoprotein E)\n\n**Confidence:** 0.82\n\n**Rationale:** The APOE ε4 allele demonstrates odds ratios of 3-4 for AD, providing substantial statistical power for fine-mapping. Preliminary fine-mapping studies (Karch et al., 2022) have already demonstrated posterior probabilities >0.85 for specific tagging variants.\n\n---\n\n## Hypothesis 2: Multi-Omics Integration Will Sharpen Credible Sets by 40-60%\n\n**Description:** Incorporating brain-derived epigenetic priors (ATAC-seq from microglia, H3K27ac ChIP-seq from neuronal nuclei) as annotation-informed Bayesian priors will substantially reduce credible set sizes. The hypothesis proposes that the combination of chromatin accessibility and active enhancer marks will concentrate posterior probability on functional regulatory variants rather than tagging SNPs.\n\n**Target Gene/Protein:** INPP5D (phosphoinositide-5-phosphatase) / PLCG2 pathway\n\n**Confidence:** 0.76\n\n**Rationale:** Microglia-specific ATAC-seq from human brain (Nott et al., 2019) identified regulatory variants in AD loci that would not appear in blood-based assays. Integration of these data as priors is mathematically equivalent to informative prior specification in Bayesian frameworks.\n\n---\n\n## Hypothesis 3: Allelic Heterogeneity Will Confound Single-Variant Credible Sets in 3-5 Loci\n\n**Description:** Approximately 3-5 of the top 25 loci will demonstrate allelic heterogeneity—multiple independent causal variants with modest effects. Standard fine-mapping assumes a single causal variant per signal, but loci like BIN1 and CLU show evidence of multiple independent signals in conditional analyses. This will result in inflated credible set sizes and posterior probability dilution.\n\n**Target Gene/Protein:** BIN1 (Bridging Integrator 1)\n\n**Confidence:** 0.68\n\n**Rationale:** Conditional GWAS analyses (Bellenguez et al., 2022) identified secondary signals at BIN1, CLU, and PTK2B. Standard fine-mapping implementations (FINEMAP, CAVIAR) can accommodate multiple causal variants but require larger sample sizes for stable estimation.\n\n---\n\n## Hypothesis 4: Brain eQTL Colocalization Will Increase Variant-Level Confidence by Factor of 2.5\n\n**Description:** Bayesian colocalization using brain-specific eQTL data (PsychENCODE, ROS/MAP) will identify variants with concordant GWAS and expression signals, effectively doubling or tripling the posterior probability that specific variants are causal. This represents a form of \"triangulation\" where statistical and functional evidence converge.\n\n**Target Gene/Protein:** MS4A gene cluster (MS4A6A, MS4A4A)\n\n**Confidence:** 0.74\n\n**Rationale:** The MS4A locus demonstrates strong eQTL effects in brain tissue (Foltyn et al., 2022), and the lead GWAS variant rs6591561 sits in high LD with expression-modulating variants. Colocalization posterior probabilities (e.g., using coloc R package) typically exceed 0.80 when both signals are present.\n\n---\n\n## Hypothesis 5: Low-LD Loci Will Yield Unacceptably Large Credible Sets (>50 variants)\n\n**Description:** Loci in genomic regions with sparse LD architecture—particularly those near centromeres or chromosomal arms—will produce credible sets containing >50 variants, rendering mechanistic interpretation infeasible. The hypothesis suggests that for these loci, variant-level inference is statistically underpowered with current sample sizes.\n\n**Target Gene/Protein:** CASS4 (Cas-related scaffolding protein 4)\n\n**Confidence:** 0.71\n\n**Rationale:** CASS4 demonstrates the smallest effect size among top AD loci (OR ~1.1) combined with a recombination hotspot flanking the gene. Without strong LD \"anchors,\" posterior probability diffuses across many plausible candidates.\n\n---\n\n## Hypothesis 6: Cell-Type Specific Regulatory Architecture Will Reveal Microglia-Predominant Causal Variants\n\n**Description:** Fine-mapping will identify a subset of variants whose posterior probability increases specifically when microglia-specific regulatory annotations are incorporated. These variants likely affect enhancers active in myeloid cells, consistent with AD genetic architecture enrichment in microglia.\n\n**Target Gene/Protein:** MEF2C (myocyte enhancer factor 2C)\n\n**Confidence:** 0.79\n\n**Rationale:** MEF2C shows microglia-specific expression quantitative trait effects, and functional studies demonstrate MEF2C regulates microglial homeostatic genes (Kobayashi et al., 2018). Bayesian priors emphasizing myeloid chromatin states should concentrate posterior mass on enhancers active in this lineage.\n\n---\n\n## Hypothesis 7: Multi-Ancestry Meta-Analysis Will Halve Credible Set Sizes Through Haplotype Diversity\n\n**Description:** Incorporating non-European ancestry cohorts (African American, East Asian, Hispanic) will reduce credible set sizes by approximately 50% due to different LD patterns and recombination histories. The hypothesis proposes that haplotype diversity across ancestries resolves causal variant identity in European-only analyses.\n\n**Target Gene/Protein:** SORL1 (sortilin-related receptor 1)\n\n**Confidence:** 0.66\n\n**Rationale:** SORL1 rare variants demonstrate AD association across multiple ancestries (CampELO et al., 2019), suggesting consistent genetic architecture. Fine-mapping in admixed populations can break down LD correlations that obscure causal variant identification in homogeneous samples.\n\n---\n\n## Summary Table\n\n| Hypothesis | Primary Mechanism | Confidence |\n|------------|-------------------|------------|\n| 1 | Strong LD enables narrow credible sets | 0.82 |\n| 2 | Multi-omics integration sharpens inference | 0.76 |\n| 3 | Allelic heterogeneity confounds standard models | 0.68 |\n| 4 | Brain eQTL colocalization doubles confidence | 0.74 |\n| 5 | Sparse LD yields impractically large sets | 0.71 |\n| 6 | Microglia-specific regulatory variants identified | 0.79 |\n| 7 | Multi-ancestry analysis halves set sizes | 0.66 |\n\n---\n\n**Key Assumptions & Limitations:**\n- Sample sizes assumed at ~200K+ individuals (current largest AD GWAS meta-analyses)\n- Functional annotation resources assumed to cover relevant brain cell types\n- Allelic heterogeneity hypothesis requires multi-signal fine-mapping software (e.g., SuSiE, DAP)\n- Multi-ancestry hypothesis depends on sufficient non-European sample sizes (currently limited for AD)",
  "tokens_used": "1709"
}